An Apparent Fatal Overdose of Terodiline

Cattini, R.A.P.; Makin, H. L. J.; Trafford, D.J.H.; Vanezis, Peter

doi:10.1093/jat/13.2.110

Cited by 5 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This drug was first introduced in the UK for urinary urgency and frequency in July 1986. A report of the sudden unexpected death of a previously healthy 20-year-old man, following an overdose in 1987, first raised the suspicions of its proarrhythmic potential [ 49 ]. The first proarrhythmic reactions to clinical doses of terodiline were also reported to the UK regulatory authority in 1987, when there was one case of ventricular tachycardia and one of bradycardia [ 37 ].…”

Section: Published Case Reports Major Drug Disasters and Regulatory mentioning

confidence: 99%

Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and Therapeutics

Shah¹

2017

Drug Saf - Case Rep

View full text Add to dashboard Cite

This article, which encourages physicians to publish case reports of adverse drug reactions (ADRs), is a review of how well-documented published case reports have contributed to promoting public safety and health and thus served to advance basic pharmacology. The origin of a number of regulatory guidelines can ultimately be traced to safety concerns triggered by such reports. It illustrates how case reports of ADRs, when coupled with simultaneous monitoring of drug pharmacokinetics, have also led to further investigations resulting in major advances in pharmacology, especially pharmacogenetics, mechanisms of drug–drug interactions and modulation of drug metabolism during inflammatory co-morbidities. Published case reports differ significantly from spontaneous case reports since they enjoy quality-compliant peer review and an immediate wider visibility among the readership, triggering others to report similar cases, and ultimately leading to prescribing restrictions on or withdrawals of the drug from the market depending on the risk. Therefore, the reporter should not be discouraged by (a) the unusual or bizarre nature of the reaction; (b) the interval, however long, from commencing drug administration to the onset of the suspected reaction; (c) however well-known the drug or the period for which it has been on the market; and (d) any pressure not to publish. Case reports should be published in reputable journals that are searchable through databases such as PubMed.

show abstract

Section: Published Case Reports Major Drug Disasters and Regulatory mentioning

confidence: 99%

Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and Therapeutics

Shah¹

2017

Drug Saf - Case Rep

View full text Add to dashboard Cite

show abstract

“…The identification by GC/MS of a novel byproduct in the tissue and fluid extracts of a victim of fatal overdoses of the tricyclic antidepressant amoxapine and aspirin has been presented (344). Mass fragmentation was used to quantify terodiline in blood and urine from a fatal overdose victim (345). An analytical method for the determination of sulfide in brain tissue from victims of hydrogen sulfide inhalation has been described (346).…”

mentioning

confidence: 99%